NCR2 and acute myeloid leukemia: These results imply that NKp44 plays a key role in NK cell responsiveness toward AML tumors, but exclusive expression of the ITIM-containing NKp44-1 isoform can stifle these beneficial responses, presumably through inhibitory signaling, thereby resulting in poor patient outcome.